DOCSLIB.ORG

1 Causes of Nausea and Vomiting and Drug Classes Used to Control

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1 Causes of Nausea and Vomiting and Drug Classes Used to Control Causes of nausea and vomiting and Drug Classes used to control nausea and vomiting Etiology Site affected Neurotransmitters & Anti-emetics by drug class receptors involved GI- Infection or Chemoreceptors and Serotonin (5-HT3) D2 receptor antagonists related (Abdominal/pelvic) radiotherapy mechanoreceptors of Dopamine (D2) Prokinetic agents (D2, 5-HT3, 5HT4) gastrointestinal tract 5-HT3 receptor antagonists Gastric stasis Chemoreceptors and Serotonin (5-HT3) Prokinetic agents (D2, 5-HT3, 5HT4) mechanoreceptors of Dopamine (D2) gastrointestinal tract Biliary duct distension Chemoreceptors and Serotonin (5-HT3) Corticosteroids mechanoreceptors of Dopamine (D2) Prokinetic agents (D2, 5-HT3, 5HT4) gastrointestinal tract Gastric/abdominal neoplasia Chemoreceptors and Serotonin (5-HT3) Prokinetic agents (D2, 5-HT3, 5HT4) Hepatic metastases mechanoreceptors of Dopamine (D2) Corticosteroids Hepatic distension gastrointestinal tract Carcinomatosis Gastric irritation or inflammation Chemoreceptors and Serotonin (5-HT3) Gastroprotective agents, PPI, anti-H2, mechanoreceptors of Dopamine (D2) antacids gastrointestinal tract Constipation Chemoreceptors and Serotonin (5-HT3) Laxatives mechanoreceptors of Dopamine (D2) gastrointestinal tract Bowel obstruction Chemoreceptors and Serotonin (5-HT3) See presentation mechanoreceptors of Dopamine (D2) gastrointestinal tract Visceral pain Chemoreceptors and Serotonin (5-HT3) Treat the pain mechanoreceptors of Dopamine (D2) D2 receptor antagonists gastrointestinal tract Prokinetic agents (D2, 5-HT3, 5HT4) 5-HT3 receptor antagonists 1 Central: Medication: Opioids Chemoreceptor trigger Dopamine (D2) D2 receptor antagonists Medications zone (CTZ) Serotonin (5-HT3) Prokinetic agents (D2, 5-HT3, 5HT4) Medication: Chemotherapy Chemoreceptor trigger Dopamine (D2) 5-HT3 receptor antagonists zone (CTZ) Serotonin (5-HT3) D2 receptor antagonists Prokinetic agents (D2, 5-HT3, 5HT4) Corticosteroids NK-1 receptor antagonists Medication: Chemoreceptor trigger Dopamine (D2) D2 receptor antagonists Estrogen zone (CTZ) Serotonin (5-HT3) Digoxin Iron Potassium Antibiotics Others Central: Vestibular disorder, local Vestibular apparatus Histamine (H1) Anticholinergics (Achm) Vestibular tumour invasion of cranial and labyrinth Acetycholine (Achm) nerve VIII Opioids Central: Metabolic: Chemoreceptor trigger Dopamine (D2) D2 receptor antagonists Metabolic Renal failure zone (CTZ) Serotonin (5-HT3) Corticosteroids Hypercalcemia If possible, treat underlying cause Uremia Ketoacidosis Hyponatremia Tumoural peptides Central: Psychological stimuli: Cerebral cortex GABA Benzodiazepines High CNS Emotions, Odours, Sounds Vision Central: Intracranial hypertension Cerebral cortex GABA Corticosteroids Raised ICP Cerebral tumour or metastases Carcinomatous meningitis Adapted from Simard M. Nausea and Vomiting. In Néron A, ed. Care beyond cure: Management of Pain and Other Symptoms, 4th ed. Montréal: Association des pharmaciens des établissements de santé du Québec; 2009: Chapter 9. 2 Drugs used to control nausea and vomiting Site of action/Receptor Drug class Drug name Chemoreceptor trigger zone (CTZ) Prokinetic agents Domperidone (Motilium®) Metoclopromide (Maxeran®, Reglan®, Metonia®) Chemoreceptor trigger zone (CTZ) Neuroleptics (antipsychotics) Chlorpromazine (Largactil®) Haloperidol (Haldol®) Methotrimeprazine (Nozinan®) Prochloperazine (Stemetil®) Olanzapine (Zyprexa®, Zyprexa Zydis®) Selective 5HT3 receptor antagonists Setrons Granisetron (Kytril®) Ondansetron (Zofran®) Vestibular apparatus and Vomiting Dimenhydrinate (Gravol®) Centre Diphenhydramine (Benadryl®) Hydroxyzine (Atarax®) Atropine Scopolamine/hyoscine hydrobromide (Transderm-V®, Scopolamine HCI) Scopolamine butylbromide (Buscopan®) Unknown Corticosteroids Dexamethasone (Decadron®) Prednisone (Deltasone®) Cortex Benzodiazepines Lorazepam (Ativan®) Oxazepam (Serax®) Midazolam (Versed®) Various CNS Cannabinoids Dronabinol (Marinol®) Nabilone (Cesamet®) Various CNS Neurokinin-I receptor Aprepitant (Emend®) antagonists Others Octreotide (Sandostatin®, Sandostatin LAR®) Adapted from Simard M. Nausea and Vomiting. In Néron A, ed. Care beyond cure: Management of Pain and Other Symptoms, 4th ed. Montréal: Association des pharmaciens des établissements de santé du Québec; 2009: Chapter 9. 3 .
Load more

Recommended publications
  • Selegiline Orally Disintegrating Tablet in the Treatment of Parkinson's Disease
    DRUG PROFILE Selegiline orally disintegrating tablet in the treatment of Parkinson’s disease Anthony Clarke & Mono- and adjunctive therapy with the oral monoamine oxidase B inhibitor selegiline has Joseph Jankovic† been used to treat motor complications resulting from long-term treatment of Parkinson’s †Author for correspondence disease. However, oral selegiline undergoes extensive first-pass metabolism resulting in low Parkinson’s Disease Center and Movement Disorders bioavailability and production of amphetamine and other metabolites, as well as Clinic, Baylor College of compromised efficacy and tolerability. An orally disintegrating tablet of selegiline utilizing Medicine, Department of Zydis® technology undergoes markedly reduced presystemic metabolism, thus providing Neurology, The Smith Tower, Suite 1801 higher plasma concentrations and lower levels of amphetamine metabolites. As an adjunct 6550 Fannin, Houston, to levodopa, selegiline orally disintegrating tablet has been found to significantly reduce TX 77030, USA ‘off’ time, increase ‘on’ time, and improve motor function in Parkinson’s disease patients Tel.: +1 713 798 5998 Fax: +1 713 798 6808 experiencing ‘wearing off’ episodes. This article provides an overview of the Zydis [email protected] technology, the rationale for its application in delivering selegiline, and results from clinical trials of selegiline orally disintegrating tablet in patients with Parkinson’s disease. Although conventional oral administration is study was carried out in part to evaluate poten- the preferred and more convenient route of tially neuroprotective effects of selegiline in drug delivery, it has some disadvantages. Phar- patients with early PD. While results demon- macokinetic limitations to conventional oral strated that selegiline conferred some clinical administration can include poor absorption and benefit, they did not permit any conclusions enzymatic degradation of the drug within the regarding the medication’s neuroprotective effects gastrointestinal tract.
    [Show full text]
  • Patient Information Leaflet
    Package leaflet : Information for the User anti-arrhythmic medicines, used to treat an uneven heart beat, as these medicines may interact with Zofran & affect the rhythm of the ® heart Zofran Zydis 4mg beta-blocker medicines used to treat certain heart or eye problems, anxiety or prevent migraines, as these medicines may interact with oral lyophilisate Zofran and affect the rhythm of the heart tramadol, a pain killer, as Zofran may reduce the effect of tramadol ondansetron medicines that affect the heart (such as haloperidol or methadone) cancer medicines (especially anthracyclines) as these may interact Read all of this leaflet carefully before you start taking this with Zofran to cause heart arrhythmias medicine because it contains important information for you. medicines used to treat depression and/or anxiety: Keep this leaflet. You may need to read it again. • SSRIs (selective serotonin reuptake inhibitors) including If you have any further questions about your illness or your fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, medicine, ask your doctor, nurse or pharmacist. escitalopram This medicine has been prescribed for you only. Do not pass it on • SNRIs (serotonin noradrenaline reuptake inhibitors) including to others. It may harm them, even if their signs of illness are the venlafaxine, duloxetine same as yours. If you are not sure if any of the above applies to you, talk to your doctor, If you get any side effects, talk to your doctor, nurse or pharmacist. nurse or pharmacist before having Zofran Zydis. This includes any possible side effects not listed in this leaflet. Pregnancy, breast-feeding and fertility What is in this leaflet: 1.
    [Show full text]
  • The Effect of Carotid Chemoreceptor Inhibition on Exercise Tolerance in Chronic Obstructive Pulmonary Disease: a Randomized-Controlled Crossover Trial
    Respiratory Medicine 160 (2019) 105815 Contents lists available at ScienceDirect Respiratory Medicine journal homepage: http://www.elsevier.com/locate/rmed The effect of carotid chemoreceptor inhibition on exercise tolerance in chronic obstructive pulmonary disease: A randomized-controlled crossover trial a,b � a,c a a Devin B. Phillips , Sophie E. Collins , Tracey L. Bryan , Eric Y.L. Wong , M. Sean McMurtry d, Mohit Bhutani a, Michael K. Stickland a,e,* a Division of Pulmonary Medicine, Faculty of Medicine and Dentistry, University of Alberta, Canada b Faculty of Kinesiology, Sport, and Recreation, University of Alberta, Canada c Faculty of Rehabilitation Medicine, University of Alberta, Canada d Division of Cardiology, Faculty of Medicine and Dentistry, University of Alberta, Canada e G.F. MacDonald Centre for Lung Health, Covenant Health, Edmonton, Alberta, Canada ARTICLE INFO ABSTRACT Keywords: Background: Patients with chronic obstructive pulmonary disease (COPD) have an exaggerated ventilatory COPD response to exercise, contributing to exertional dyspnea and exercise intolerance. We recently demonstrated Exercise tolerance enhanced activity and sensitivity of the carotid chemoreceptor (CC) in COPD which may alter ventilatory and Carotid chemoreceptor cardiovascular regulation and negatively affect exercise tolerance. We sought to determine whether CC inhibi­ Dyspnea tion improves ventilatory and cardiovascular regulation, dyspnea and exercise tolerance in COPD. Methods: Twelve mild-moderate COPD patients (FEV1 83 � 15 %predicted) and twelve age- and sex-matched healthy controls completed two time-to-symptom limitation (TLIM) constant load exercise tests at 75% peak À À power output with either intravenous saline or low-dose dopamine (2 μg⋅kg 1⋅min 1, order randomized) to inhibit the CC.
    [Show full text]
  • Oral Delivery Oct 06 18/1/07 20:19 Page 1
    Oral Delivery Oct 06 18/1/07 20:19 Page 1 ORAL DRUG DELIVERY WHEN YOU FIND THE HOLY GRAIL www.ondrugdelivery.com Oral Delivery Oct 06 18/1/07 20:19 Page 2 “Oral drug delivery: when you find the Holy Grail” CONTENTS This edition is one in a series of sponsored themed publications from ONdrugDelivery Ltd. Each issue focuses on a specific topic within the field of drug delivery, and contain up to eight articles contributed Introductory comment by leaders in that field. Guy Furness 3 Full contact information appears alongside each article. Contributing companies would be delighted to hear Growing sales and new opportunities for oral from interested readers directly. ONdrugDelivery fast dissolve would also be very pleased to pass on to authors, or Dr Ian Muir answer as appropriate, any queries you might have in relation to this publication or others in the series. Cardinal Health 4-6 During 2007 ONdrugDelivery will be covering the following topics: From oral drug delivery technology to proprietary February: Transdermal delivery product development April: Pulmonary delivery Dr Anand Baichwal, Thomas Sciascia, MD June: Prefilled syringes Penwest Pharmaceuticals 7-10 August: Oral drug delivery October: Delivering injectables December: Nanotechnology in drug delivery Combination oral products: the time is now! Fred H. Miller To start a FREE subscription (pdf or print) to INNERCAP Technologies 12-15 ONdrugDelivery’s sponsored series, please contact ONdrugDelivery directly (details below) Combining technologies without compromise: taste masking + ODT + modified release Steve Ellul Eurand 16-19 Oral drug delivery: the Holy Grail To find out more about how your company can Ms Bavani Shankar participate in 2007, please contact ONdrugDelivery Emisphere Technologies 20-21 directly (details below).
    [Show full text]
  • Alternative Forms of Oral Drug Delivery for Pediatric Patients Marcia L
    PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the University of Virginia Children’s Hospital Volume 19 Number 3 March 2013 Alternative Forms of Oral Drug Delivery for Pediatric Patients Marcia L. Buck, Pharm.D., FCCP, FPPAG he lack of an appropriate dosage form the concentration versus time curve (AUC) of T limits the use of many medications that 45% for lopinavir and 47% for ritonavir (p = may potentially benefit children. While this has 0.003 and 0.006, respectively). been a long-standing problem for pediatric healthcare providers, little attention has been Cutting tablets, another common practice, may paid to remedying it until recently. In 2005 the be acceptable for some drugs, however this Eunice Kennedy Shriver National Institute for practice can introduce considerable variability Child Health and Human Development, joined between doses. In drugs with a narrow by representatives from the Food and Drug therapeutic index, such as levothyroxine, this Administration (FDA), academic medicine, and variability may be enough to produce clinically the pharmaceutical industry, formed the United significant changes in clinical response.7 When States (US) Pediatric Formulations Initiative in cutting a tablet is necessary, family members an effort to stimulate research in pediatric should receive specific instructions on the formulation technology.1 Similar work by the process, including the proper use of a tablet European Medication Agency (EMA) led to the splitter. Family members involved in dose development of the European Pediatric preparation should also understand how to Formulation Initiative.2 In addition, the World dispose of unused drug and the need to avoid Health Organization launched a global initiative repeated exposure to drugs that have in 2007 entitled “Make Medicines Child Size” to carcinogenic or teratogenic properties.
    [Show full text]
  • Visions & Reflections on the Origin of Smell: Odorant Receptors in Insects
    Cell. Mol. Life Sci. 63 (2006) 1579–1585 1420-682X/06/141579-7 DOI 10.1007/s00018-006-6130-7 Cellular and Molecular Life Sciences © Birkhäuser Verlag, Basel, 2006 Visions & Reflections On the ORigin of smell: odorant receptors in insects R. Benton Laboratory of Neurogenetics and Behavior, The Rockefeller University, 1230 York Avenue, Box 63, New York, New York 10021 (USA), Fax: +1 212 327 7238, e-mail: [email protected] Received 23 March 2006; accepted 28 April 2006 Online First 19 June 2006 Abstract. Olfaction, the sense of smell, depends on large, suggested that odours are perceived by a conserved mecha- divergent families of odorant receptors that detect odour nism. Here I review recent revelations of significant struc- stimuli in the nose and transform them into patterns of neu- tural and functional differences between the Drosophila ronal activity that are recognised in the brain. The olfactory and mammalian odorant receptor proteins and discuss the circuits in mammals and insects display striking similarities implications for our understanding of the evolutionary and in their sensory physiology and neuroanatomy, which has molecular biology of the insect odorant receptors. Keywords. Olfaction, odorant receptor, signal transduction, GPCR, neuron, insect, mammal, evolution. Olfaction: the basics characterised by the presence of seven membrane-span- ning segments with an extracellular N terminus. OR pro- Olfaction is used by most animals to extract vital infor- teins are exposed to odours on the ciliated endings of olf- mation from volatile chemicals in the environment, such actory sensory neuron (OSN) dendrites in the olfactory as the presence of food or predators.
    [Show full text]
  • The Aer Protein and the Serine Chemoreceptor Tsr Independently
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 10541–10546, September 1997 Biochemistry The Aer protein and the serine chemoreceptor Tsr independently sense intracellular energy levels and transduce oxygen, redox, and energy signals for Escherichia coli behavior (signal transductionybacterial chemotaxisyaerotaxis) ANURADHA REBBAPRAGADA*, MARK S. JOHNSON*, GORDON P. HARDING*, ANTHONY J. ZUCCARELLI*†, HANSEL M. FLETCHER*, IGOR B. ZHULIN*, AND BARRY L. TAYLOR*†‡ *Department of Microbiology and Molecular Genetics and †Center for Molecular Biology and Gene Therapy, School of Medicine, Loma Linda University, Loma Linda, CA 92350 Edited by Daniel E. Koshland, Jr., University of California, Berkeley, CA, and approved July 17, 1997 (received for review May 6, 1997) ABSTRACT We identified a protein, Aer, as a signal conformational change in the signaling domain that increases transducer that senses intracellular energy levels rather than the rate of CheA autophosphorylation. The phosphoryl resi- the external environment and that transduces signals for due from CheA is transferred to CheY, which, in its phos- aerotaxis (taxis to oxygen) and other energy-dependent be- phorylated state, binds to a switch on the flagellar motors and havioral responses in Escherichia coli. Domains in Aer are signals a reversal of the direction of rotation of the flagella. similar to the signaling domain in chemotaxis receptors and Evidence that CheA, CheW, and CheY are also part of the the putative oxygen-sensing domain of some transcriptional aerotaxis response (12) led us to propose that the aerotaxis activators. A putative FAD-binding site in the N-terminal transducer would have (i) a C-terminal domain homologous to domain of Aer shares a consensus sequence with the NifL, Bat, the chemoreceptor signaling domain that modulates CheA and Wc-1 signal-transducing proteins that regulate gene autophosphorylation and (ii) a domain that senses oxygen.
    [Show full text]
  • Olanzapine (Zyprexa, Zydis) ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES
    Olanzapine (Zyprexa, Zydis) ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES Client’s Name ______________________________________________________ Date _____________________ Initial Medication Instructions __________________________________________________________________ What does this medication help to treat? Schizophrenia, schizoaffective disorder, bipolar disorder or other conditions. Symptoms of these conditions are: Poor concentration Hallucinations (hearing voices) Rapid thoughts Delusions (beliefs that are false) Pacing and restlessness Fearful feelings Fluctuations in mood Paranoia or suspiciousness Insomnia Agitation, aggression, or hostility Olanzapine is sometimes prescribed for other uses; ask your Lack of energy or motivation health care professional for more information Other information . This medication can take up to 6 weeks to achieve desired results, but you should begin to see improvement within the first two weeks of treatment. It is very important to keep all appointments with your clinic, prescriber, or laboratory. Side Effects and Management Common (greater than 10 in 100 clients on this medication) Drowsiness Use caution when driving or operating machinery. Ask you prescriber about taking your dose at bedtime if drowsiness occurs. Weight Gain and Avoid foods high in fat and sugar. Eat balanced meals and maintain an active lifestyle. Individuals Increased appetite may gain 10-15 pounds over 1-2 months. Dizziness Arise slowly from chairs. Dangle feet off the side of the bed before getting up. Headache You may take aspirin or Tylenol to relieve your headache. The headache side effect of this medication should subside over time. Talk to your prescriber if headaches are severe or persist for more than one day. Restlessness, Agitation Talk to your prescriber about possibly adjusting the dose of your olanzapine.
    [Show full text]
  • Chemical and Electric Transmission in the Carotid Body Chemoreceptor Complex
    EYZAGUIRRE Biol Res 38, 2005, 341-345 341 Biol Res 38: 341-345, 2005 BR Chemical and electric transmission in the carotid body chemoreceptor complex CARLOS EYZAGUIRRE Department of Physiology, University of Utah School of Medicine, Research Park, Salt Lake City, Utah, USA ABSTRACT Carotid body chemoreceptors are complex secondary receptors. There are chemical and electric connections between glomus cells (GC/GC) and between glomus cells and carotid nerve endings (GC/NE). Chemical secretion of glomus cells is accompanied by GC/GC uncoupling. Chemical GC/NE transmission is facilitated by concomitant electric coupling. Chronic hypoxia reduces GC/GC coupling but increases G/NE coupling. Therefore, carotid body chemoreceptors use chemical and electric transmission mechanisms to trigger and change the sensory discharge in the carotid nerve. Key terms: carotid body, chemosensory activity, glomus cells. The subject of this short review is highly Years later, with the advent of the appropriate since we are honoring Prof. electron microscope, it was found that the Patricio Zapata who has been a pioneer in glomus cells were connected synaptically this field and has done extensive to the carotid nerve endings (for refs. see pharmacological studies on chemical Mc Donald, 1981; Verna, 1997). Then, the synaptic transmission in the carotid body. problems started because of the location of Dr. Zapata is an excellent scientist and clear core synaptic vesicles. At the time, teacher, and I dearly value him as a friend these structures were supposed to be a and colleague. marker of pre-synaptic elements, and in the carotid body, they appeared some times in the glomus cells but very often in NATURE OF THE CAROTID BODY INNERVATION carotid nerve endings.
    [Show full text]
  • The Role of Chemoreceptor Evolution in Behavioral Change Cande, Prud’Homme and Gompel 153
    Available online at www.sciencedirect.com Smells like evolution: the role of chemoreceptor evolution in behavioral change Jessica Cande, Benjamin Prud’homme and Nicolas Gompel In contrast to physiology and morphology, our understanding success. How an organism interacts with its environment of how behaviors evolve is limited.This is a challenging task, as can be divided into three parts: first, the sensory percep- it involves the identification of both the underlying genetic tion of diverse auditory, visual, tactile, chemosensory or basis and the resultant physiological changes that lead to other cues; second, the processing of this information by behavioral divergence. In this review, we focus on the central nervous system (CNS), leading to a repres- chemosensory systems, mostly in Drosophila, as they are one entation of the sensory signal; and third, a behavioral of the best-characterized components of the nervous system response. Thus, behaviors could evolve either through in model organisms, and evolve rapidly between species. We changes in the peripheral nervous system (PNS) (e.g. examine the hypothesis that changes at the level of [1 ]), or through changes in higher-order neural circuitry chemosensory systems contribute to the diversification of (Figure 1). While the latter remain elusive, recent work behaviors. In particular, we review recent progress in on chemosensation in insects illustrates how the PNS understanding how genetic changes between species affect shapes behavioral evolution. chemosensory systems and translate into divergent behaviors. A major evolutionary trend is the rapid Chemosensation in insects depends on three classes of diversification of the chemoreceptor repertoire among receptors expressed in peripheral neurons housed in species.
    [Show full text]
  • Signaling and Sensory Adaptation in Escherichia Coli Chemoreceptors
    Review Special Issue: Microbial Translocation Signaling and sensory adaptation in Escherichia coli chemoreceptors: 2015 update 1 2 3 John S. Parkinson , Gerald L. Hazelbauer , and Joseph J. Falke 1 Department of Biology, University of Utah, 257 South 1400 East, Salt Lake City, UT 84112, USA 2 Department of Biochemistry, University of Missouri Columbia, Columbia, MO 65211, USA 3 Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO 80309, USA Motile Escherichia coli cells track gradients of attractant sensitivity to ambient conditions, allowing chemoreceptors and repellent chemicals in their environment with trans- to operate over a wide concentration range. membrane chemoreceptor proteins. These receptors How do chemoreceptors process stimulus and sensory operate in cooperative arrays to produce large changes adaptation signals? How do they control CheA activity in in the activity of a signaling kinase, CheA, in response to response to those signals? What is the structure of the core small changes in chemoeffector concentration. Recent receptor signaling complex? How are those units net- research has provided a much deeper understanding of worked to produce cooperative signaling behavior? Over the structure and function of core receptor signaling the past few years of chemoreceptor research, molecular complexes and the architecture of higher-order receptor answers to these questions have come into sharper focus. arrays, which, in turn, has led to new insights into the In this brief review we summarize evidence for an emerg- molecular signaling mechanisms of chemoreceptor net- ing dynamics-based view of receptor operation and how it works. Current evidence supports a new view of recep- can account for transmission of stimulus and sensory tor signaling in which stimulus information travels adaptation signals through chemoreceptor molecules.
    [Show full text]
  • Olfactory Sensitivity in Mammalian Species
    Physiol. Res. 65: 369-390, 2016 https://doi.org/10.33549/physiolres.932955 REVIEW Olfactory Sensitivity in Mammalian Species M. WACKERMANNOVÁ1, L. PINC2, †L. JEBAVÝ3 1Department of Zoology and Fisheries, Faculty of Agrobiology, Food and Natural Resources, Czech University of Life Sciences Prague, Czech Republic, 2Canine Behavior Research Center, Department of Animal Science and Ethology, Faculty of Agrobiology, Food and Natural Resources, Czech University of Life Sciences Prague, Czech Republic, 3Department of Animal Science and Ethology, Faculty of Agrobiology, Food and Natural Resources, Czech University of Life Sciences Prague, Czech Republic Received November 13, 2014 Accepted February 5, 2016 On-line April 12, 2016 Summary Corresponding author Olfaction enables most mammalian species to detect and M. Wackermannová, Department of Zoology and Fisheries, discriminate vast numbers of chemical structures called odorants Faculty of Agrobiology, Food and Natural Resources, Czech and pheromones. The perception of such chemical compounds is University of Life Sciences Prague, Kamycka 129, 160 00 mediated via two major olfactory systems, the main olfactory Prague 6, Czech Republic. E-mail: [email protected] system and the vomeronasal system, as well as minor systems, such as the septal organ and the Grueneberg ganglion. Distinct Introduction differences exist not only among species but also among individuals in terms of their olfactory sensitivity; however, little is Chemosensory systems develop very early in known about the mechanisms that determine these differences. ontogeny and are found in almost every animal. The In research on the olfactory sensitivity of mammals, scientists mammalian sense of smell detects and discriminates thus depend in most cases on behavioral testing.
    [Show full text]